Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.07
ENDP's Cash-to-Debt is ranked lower than
94% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. ENDP: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
ENDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.05 Max: No Debt
Current: 0.07
Equity-to-Asset 0.07
ENDP's Equity-to-Asset is ranked lower than
97% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ENDP: 0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
ENDP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.5 Max: 0.77
Current: 0.07
0.07
0.77
Debt-to-Equity 10.24
ENDP's Debt-to-Equity is ranked lower than
99% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. ENDP: 10.24 )
Ranked among companies with meaningful Debt-to-Equity only.
ENDP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 1.33 Max: 10.24
Current: 10.24
0.01
10.24
Debt-to-EBITDA -2.75
ENDP's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. ENDP: -2.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ENDP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.13  Med: 0.67 Max: 6.42
Current: -2.75
-20.13
6.42
Piotroski F-Score: 4
Altman Z-Score: -1.52
Beneish M-Score: -5.05
WACC vs ROIC
2.22%
-34.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -98.65
ENDP's Operating Margin % is ranked lower than
87% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. ENDP: -98.65 )
Ranked among companies with meaningful Operating Margin % only.
ENDP' s Operating Margin % Range Over the Past 10 Years
Min: -98.65  Med: 21.38 Max: 30.74
Current: -98.65
-98.65
30.74
Net Margin % -126.93
ENDP's Net Margin % is ranked lower than
87% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. ENDP: -126.93 )
Ranked among companies with meaningful Net Margin % only.
ENDP' s Net Margin % Range Over the Past 10 Years
Min: -126.93  Med: -9.43 Max: 20.95
Current: -126.93
-126.93
20.95
ROE % -142.33
ENDP's ROE % is ranked lower than
94% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. ENDP: -142.33 )
Ranked among companies with meaningful ROE % only.
ENDP' s ROE % Range Over the Past 10 Years
Min: -142.33  Med: -12.88 Max: 20.43
Current: -142.33
-142.33
20.43
ROA % -34.00
ENDP's ROA % is ranked lower than
86% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ENDP: -34.00 )
Ranked among companies with meaningful ROA % only.
ENDP' s ROA % Range Over the Past 10 Years
Min: -34  Med: -2.47 Max: 14.68
Current: -34
-34
14.68
ROC (Joel Greenblatt) % -604.71
ENDP's ROC (Joel Greenblatt) % is ranked lower than
90% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. ENDP: -604.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENDP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -604.71  Med: 81.95 Max: 718.27
Current: -604.71
-604.71
718.27
3-Year Revenue Growth Rate 0.50
ENDP's 3-Year Revenue Growth Rate is ranked lower than
68% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ENDP: 0.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENDP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12  Med: 19.6 Max: 26.9
Current: 0.5
-12
26.9
GuruFocus has detected 3 Warning Signs with Endo International PLC ENDP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENDP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ENDP Guru Trades in Q3 2016

Mario Gabelli 46,700 sh (New)
Larry Robbins 4,250,784 sh (New)
Ray Dalio 887,293 sh (New)
Jim Simons 206,060 sh (+1772.42%)
Paul Tudor Jones 59,815 sh (+245.83%)
Arnold Schneider 479,006 sh (+7.59%)
David Dreman 10,670 sh (unchged)
Pioneer Investments 28,618 sh (unchged)
John Paulson 7,953,900 sh (-11.19%)
Steven Cohen 1,762,300 sh (-30.11%)
Joel Greenblatt 28,677 sh (-97.23%)
» More
Q4 2016

ENDP Guru Trades in Q4 2016

Jim Simons 1,525,860 sh (+640.49%)
Ray Dalio 1,537,036 sh (+73.23%)
Arnold Schneider 559,211 sh (+16.74%)
Mario Gabelli 47,500 sh (+1.71%)
Larry Robbins 4,250,784 sh (unchged)
Pioneer Investments 28,618 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
John Paulson 7,839,900 sh (-1.43%)
» More
Q1 2017

ENDP Guru Trades in Q1 2017

Joel Greenblatt 744,425 sh (New)
Francis Chou 950,000 sh (New)
Steven Cohen 1,775,500 sh (New)
Paul Tudor Jones 114,416 sh (New)
Ray Dalio 3,825,502 sh (+148.89%)
Larry Robbins 10,378,390 sh (+144.15%)
Mario Gabelli 59,400 sh (+25.05%)
Arnold Schneider 642,311 sh (+14.86%)
Pioneer Investments 28,618 sh (unchged)
Jim Simons Sold Out
John Paulson 7,838,900 sh (-0.01%)
» More
Q2 2017

ENDP Guru Trades in Q2 2017

Diamond Hill Capital 488,244 sh (New)
Jim Simons 206,500 sh (New)
Steven Cohen 3,156,400 sh (+77.78%)
Joel Greenblatt 1,023,962 sh (+37.55%)
Mario Gabelli 62,700 sh (+5.56%)
Pioneer Investments 28,618 sh (unchged)
George Soros 250,000 sh (unchged)
Larry Robbins 10,378,390 sh (unchged)
Francis Chou 950,000 sh (unchged)
Arnold Schneider 631,311 sh (-1.71%)
John Paulson 7,174,490 sh (-8.48%)
Paul Tudor Jones 54,796 sh (-52.11%)
Ray Dalio 1,539,408 sh (-59.76%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Reduce -8.48%0.1%$10.29 - $13.78 $ 7.65-35%7,174,490
Joel Greenblatt 2017-06-30 Add 37.55%0.04%$10.29 - $13.78 $ 7.65-35%1,023,962
Arnold Schneider 2017-06-30 Reduce -1.71%0.02%$10.29 - $13.78 $ 7.65-35%631,311
Mario Gabelli 2017-06-30 Add 5.56%$10.29 - $13.78 $ 7.65-35%62,700
John Paulson 2017-03-31 Reduce -0.01%$9.87 - $17.7 $ 7.65-38%7,838,900
Joel Greenblatt 2017-03-31 New Buy0.11%$9.87 - $17.7 $ 7.65-38%744,425
Arnold Schneider 2017-03-31 Add 14.86%0.16%$9.87 - $17.7 $ 7.65-38%642,311
Mario Gabelli 2017-03-31 Add 25.05%$9.87 - $17.7 $ 7.65-38%59,400
John Paulson 2016-12-31 Reduce -1.43%0.03%$14.51 - $21.48 $ 7.65-57%7,839,900
Arnold Schneider 2016-12-31 Add 16.74%0.23%$14.51 - $21.48 $ 7.65-57%559,211
Mario Gabelli 2016-12-31 Add 1.71%$14.51 - $21.48 $ 7.65-57%47,500
Joel Greenblatt 2016-12-31 Sold Out 0.01%$14.51 - $21.48 $ 7.65-57%0
David Dreman 2016-12-31 Sold Out 0.13%$14.51 - $21.48 $ 7.65-57%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HZNP, NAS:SUPN, SHSE:603567, XLJU:KRKG, TSE:4521, TSE:4555, SZSE:002390, SHSE:600267, SHSE:600380, SZSE:300199, NAS:IPXL, SHSE:600329, SZSE:300110, SZSE:300601, NAS:IRWD, NAS:RDUS, TSE:4540, NAS:PCRX, XKRX:041960, XKRX:003520 » details
Traded in other countries:ENDP.Canada, EO7.Germany,
Headquarter Location:Ireland
Endo International PLC is a generics and specialty branded pharmaceutical company. The company sells generic products in the US which includes pain management, urology, central nervous system disorders, immunosuppression, and oncology and among others.

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The recent acquisitions of Auxilium and Par have increased the company's presence in urology and generics, respectively. Branded drugs represent approximately 30% of revenue with the remainder in generics.

Guru Investment Theses on Endo International PLC

Weitz Value Fund Comments on Endo International - Apr 27, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) left less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter of 2016 and refocus our capital in more attractive opportunities.



From Weitz Value Fund first quarter 2017 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jan 26, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Endo - Nov 08, 2016

Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

DEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (ENDP)
ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm
ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017
Endo to Announce Third-Quarter 2017 Financial Results
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endo International plc – ENDP
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm
Four-Time PGA TOUR Winner Tim Herron Teams Up with Endo Pharmaceuticals to Encourage Adults to Get the Facts on Hand
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm

Ratios

vs
industry
vs
history
Forward PE Ratio 2.64
ENDP's Forward PE Ratio is ranked higher than
97% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. ENDP: 2.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.08
ENDP's PB Ratio is ranked higher than
57% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. ENDP: 2.08 )
Ranked among companies with meaningful PB Ratio only.
ENDP' s PB Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.42 Max: 17.5
Current: 2.08
0.53
17.5
PS Ratio 0.43
ENDP's PS Ratio is ranked higher than
93% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. ENDP: 0.43 )
Ranked among companies with meaningful PS Ratio only.
ENDP' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 2.04 Max: 6.03
Current: 0.43
0.42
6.03
Price-to-Free-Cash-Flow 10.93
ENDP's Price-to-Free-Cash-Flow is ranked higher than
80% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. ENDP: 10.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENDP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.76  Med: 9.39 Max: 242.43
Current: 10.93
3.76
242.43
Price-to-Operating-Cash-Flow 5.57
ENDP's Price-to-Operating-Cash-Flow is ranked higher than
89% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. ENDP: 5.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENDP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.01  Med: 8.5 Max: 423.65
Current: 5.57
3.01
423.65
EV-to-EBIT -2.34
ENDP's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. ENDP: -2.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ENDP' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.3  Med: 7.6 Max: 77.3
Current: -2.34
-33.3
77.3
EV-to-EBITDA -3.15
ENDP's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. ENDP: -3.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -139  Med: 7.1 Max: 29.3
Current: -3.15
-139
29.3
EV-to-Revenue 2.33
ENDP's EV-to-Revenue is ranked higher than
60% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. ENDP: 2.33 )
Ranked among companies with meaningful EV-to-Revenue only.
ENDP' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.8 Max: 8.8
Current: 2.33
1.2
8.8
Current Ratio 1.02
ENDP's Current Ratio is ranked lower than
89% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. ENDP: 1.02 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.83 Max: 3.55
Current: 1.02
0.84
3.55
Quick Ratio 0.80
ENDP's Quick Ratio is ranked lower than
85% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. ENDP: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.62 Max: 3.34
Current: 0.8
0.61
3.34
Days Inventory 82.34
ENDP's Days Inventory is ranked higher than
72% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. ENDP: 82.34 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 80.55  Med: 99.98 Max: 148.08
Current: 82.34
80.55
148.08
Days Sales Outstanding 52.42
ENDP's Days Sales Outstanding is ranked higher than
69% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ENDP: 52.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.42  Med: 98.15 Max: 171.52
Current: 52.42
52.42
171.52
Days Payable 16.60
ENDP's Days Payable is ranked lower than
92% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. ENDP: 16.60 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 16.6  Med: 120.4 Max: 300.35
Current: 16.6
16.6
300.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.60
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ENDP: -24.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -4.75 Max: 4.7
Current: -24.6
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.43
ENDP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. ENDP: 0.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENDP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.39  Med: 0.71 Max: 2.28
Current: 0.43
0.39
2.28
Price-to-Median-PS-Value 0.21
ENDP's Price-to-Median-PS-Value is ranked higher than
97% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. ENDP: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENDP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.47 Max: 4.07
Current: 0.21
0.2
4.07
Price-to-Peter-Lynch-Fair-Value 3.62
ENDP's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. ENDP: 3.62 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ENDP' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.81 Max: 54.35
Current: 3.62
0
54.35
Earnings Yield (Greenblatt) % -42.91
ENDP's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. ENDP: -42.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENDP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -43.01  Med: 4.7 Max: 26.8
Current: -42.91
-43.01
26.8
Forward Rate of Return (Yacktman) % 54.55
ENDP's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. ENDP: 54.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENDP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 30.55 Max: 54.55
Current: 54.55
4.3
54.55

More Statistics

Revenue (TTM) (Mil) $4,039.18
EPS (TTM) $ -23.01
Beta-0.20
Short Percentage of Float9.58%
52-Week Range $7.40 - 21.87
Shares Outstanding (Mil)223.29

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 3,472 3,111 3,193 3,216
EPS ($) 3.42 2.94 3.15 3.41
EPS without NRI ($) 3.42 2.94 3.15 3.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-6.03%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}